Cargando…
Makulopathie bei Sichelzellerkrankung
BACKGROUND: Sickle cell disease (SCD) is a hereditary hemoglobinopathy, which leads to microcirculatory disturbances of various organ systems through recurrent vaso-occlusive episodes, with a possibly fatal outcome. Sickle cell retinopathy (SCR) is the best described ocular manifestation of SCD. Irr...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Medizin
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492597/ https://www.ncbi.nlm.nih.gov/pubmed/33502544 http://dx.doi.org/10.1007/s00347-020-01319-8 |
_version_ | 1784578947420258304 |
---|---|
author | Bachmeier, Isabel Blecha, Christiane Föll, Jürgen Wolff, Daniel Jägle, Herbert |
author_facet | Bachmeier, Isabel Blecha, Christiane Föll, Jürgen Wolff, Daniel Jägle, Herbert |
author_sort | Bachmeier, Isabel |
collection | PubMed |
description | BACKGROUND: Sickle cell disease (SCD) is a hereditary hemoglobinopathy, which leads to microcirculatory disturbances of various organ systems through recurrent vaso-occlusive episodes, with a possibly fatal outcome. Sickle cell retinopathy (SCR) is the best described ocular manifestation of SCD. Irrespective of the presence of peripheral SCR, sickle cell maculopathy (SCM) can occur early in the course of the disease. METHODS: Review of the international and German literature on ocular involvement in SCD with a focus on SCR and SCM and an overview of current systemic therapeutic approaches in SCD on the occasion of the presentation of two patients with HbSS SCD. RESULTS AND CONCLUSION: In contrast to SCR, SCM with temporal thinning of the inner retinal layers has only been increasingly described in the literature in the last 5 years, with the advent of SD-OCT and OCTA. Irrespective of the presence of SCR, as many as about half of the patients may develop SCM early in the course of the disease. As a result of progress in systemic therapeutic options and due to migration, the clinical picture will occur more often also in Germany. By knowing about this complication of SCD an early diagnosis can be made and unnecessary diagnostics can be avoided. |
format | Online Article Text |
id | pubmed-8492597 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Medizin |
record_format | MEDLINE/PubMed |
spelling | pubmed-84925972021-10-15 Makulopathie bei Sichelzellerkrankung Bachmeier, Isabel Blecha, Christiane Föll, Jürgen Wolff, Daniel Jägle, Herbert Ophthalmologe Übersichten BACKGROUND: Sickle cell disease (SCD) is a hereditary hemoglobinopathy, which leads to microcirculatory disturbances of various organ systems through recurrent vaso-occlusive episodes, with a possibly fatal outcome. Sickle cell retinopathy (SCR) is the best described ocular manifestation of SCD. Irrespective of the presence of peripheral SCR, sickle cell maculopathy (SCM) can occur early in the course of the disease. METHODS: Review of the international and German literature on ocular involvement in SCD with a focus on SCR and SCM and an overview of current systemic therapeutic approaches in SCD on the occasion of the presentation of two patients with HbSS SCD. RESULTS AND CONCLUSION: In contrast to SCR, SCM with temporal thinning of the inner retinal layers has only been increasingly described in the literature in the last 5 years, with the advent of SD-OCT and OCTA. Irrespective of the presence of SCR, as many as about half of the patients may develop SCM early in the course of the disease. As a result of progress in systemic therapeutic options and due to migration, the clinical picture will occur more often also in Germany. By knowing about this complication of SCD an early diagnosis can be made and unnecessary diagnostics can be avoided. Springer Medizin 2021-01-27 2021 /pmc/articles/PMC8492597/ /pubmed/33502544 http://dx.doi.org/10.1007/s00347-020-01319-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access Dieser Artikel wird unter der Creative Commons Namensnennung 4.0 International Lizenz veröffentlicht, welche die Nutzung, Vervielfältigung, Bearbeitung, Verbreitung und Wiedergabe in jeglichem Medium und Format erlaubt, sofern Sie den/die ursprünglichen Autor(en) und die Quelle ordnungsgemäß nennen, einen Link zur Creative Commons Lizenz beifügen und angeben, ob Änderungen vorgenommen wurden. Die in diesem Artikel enthaltenen Bilder und sonstiges Drittmaterial unterliegen ebenfalls der genannten Creative Commons Lizenz, sofern sich aus der Abbildungslegende nichts anderes ergibt. Sofern das betreffende Material nicht unter der genannten Creative Commons Lizenz steht und die betreffende Handlung nicht nach gesetzlichen Vorschriften erlaubt ist, ist für die oben aufgeführten Weiterverwendungen des Materials die Einwilligung des jeweiligen Rechteinhabers einzuholen. Weitere Details zur Lizenz entnehmen Sie bitte der Lizenzinformation auf http://creativecommons.org/licenses/by/4.0/deed.de (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Übersichten Bachmeier, Isabel Blecha, Christiane Föll, Jürgen Wolff, Daniel Jägle, Herbert Makulopathie bei Sichelzellerkrankung |
title | Makulopathie bei Sichelzellerkrankung |
title_full | Makulopathie bei Sichelzellerkrankung |
title_fullStr | Makulopathie bei Sichelzellerkrankung |
title_full_unstemmed | Makulopathie bei Sichelzellerkrankung |
title_short | Makulopathie bei Sichelzellerkrankung |
title_sort | makulopathie bei sichelzellerkrankung |
topic | Übersichten |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492597/ https://www.ncbi.nlm.nih.gov/pubmed/33502544 http://dx.doi.org/10.1007/s00347-020-01319-8 |
work_keys_str_mv | AT bachmeierisabel makulopathiebeisichelzellerkrankung AT blechachristiane makulopathiebeisichelzellerkrankung AT folljurgen makulopathiebeisichelzellerkrankung AT wolffdaniel makulopathiebeisichelzellerkrankung AT jagleherbert makulopathiebeisichelzellerkrankung |